血液腫瘍検査の世界市場レポート 2025年

血液腫瘍検査の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.6％で68億3,000万米ドルに成長します。予測期間の成長は、個別化医療の動向、人工知能の統合、高齢者人口の増加、ゲノム研究の進歩、がんの早期発見に対する需要の高まりに起因すると考えられます。予測期間の主な動向には、ゲノム検査の技術的進歩、非侵襲的検査のためのリキッドバイオプシー、業界における共同研究やパートナーシップ、規制状況と標準化、技術の進歩などが含まれます。

予想される血液がん罹患率の上昇は、血液腫瘍検査市場の成長の原動力となると思われます。血液がんは、血液、骨髄、リンパ系に影響を及ぼす、血液に起因するがん群を包含し、白血病、リンパ腫、骨髄腫などの疾患が含まれます。これらの疾患は早期診断が重要であり、血液腫瘍検査はそのために極めて重要な役割を果たします。一例として、米国がん協会は、2023年には白血病が約5万9,610人の米国人に影響を与え、2万3,710人の死亡につながると予測しています。さらに、非ホジキンリンパ腫は米国で8万550人が罹患し、2万180人が死亡すると予測されています。したがって、血液がんの有病率の増加は、血液腫瘍検査市場を前進させる重要な要因です。

ヘルスケア支出の増加は、今後数年間の血液腫瘍検査市場の成長を促進すると予測されています。ヘルスケア支出とは、特定の地域、国、または経済において、決められた期間にヘルスケア部門に割り当てられる公的および私的な資金の総額のことです。これらの資金を血液腫瘍検査に適切に配分することで、診断精度が向上し、個別化された治療アプローチが可能になり、複雑な造血腫瘍の分野における患者の転帰が改善されます。例えば、英国の政府機関であるOffice for National Statisticsの報告書は2024年5月に、2022～2023年にかけて総ヘルスケア支出が名目ベースで5.6％増加したことを明らかにしました。一方、2022年の成長率はわずか0.9%でした。したがって、ヘルスケア支出の増加が血液腫瘍学検査市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の血液腫瘍検査市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の血液腫瘍検査市場：成長率分析
• 世界の血液腫瘍検査市場の実績：規模と成長、2019～2024年
• 世界の血液腫瘍検査市場の予測：規模と成長、2024～2029年、2034年
• 世界の血液腫瘍検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血液腫瘍検査市場：製品・サービス別、実績と予測、2019～2024年、2024～2029年、2034年
• アッセイキットと試薬
• サービス
• 世界の血液腫瘍検査市場：がんの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 白血病
• リンパ腫
• 多発性骨髄腫
• その他
• 世界の血液腫瘍検査市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• ポリメラーゼ連鎖反応（PCR）
• 免疫組織化学（IHC）
• 次世代シーケンシング（NGS）
• その他
• 世界の血液腫瘍検査市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 学術研究機関
• その他
• 世界の血液腫瘍検査市場：アッセイキットと試薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• PCRキット
• 次世代シーケンシング（NGS）キット
• フローサイトメトリー試薬
• ELISAキット
• 抗体
• 世界の血液腫瘍検査市場：サービスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 検査サービス
• コンサルティングサービス
• データ分析サービス

第7章 地域別・国別分析

• 世界の血液腫瘍検査市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の血液腫瘍検査市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血液腫瘍検査市場：競合情勢
• 血液腫瘍検査市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Qiagen N.V.
• Bio-Rad Laboratories Inc.
• Archerdx Inc.
• ARUP Laboratories Inc.
• Asuragen Inc.
• Adaptive Biotechnologies Corp.
• Cepheid Inc.
• EntroGen Inc.
• CORE Diagnostics Inc.
• Genoptix Inc.
• GenPath Diagnostics
• NeoGenomics Laboratories Inc.
• Siemens AG
• Sysmex Corporation
• Laboratory Corporation of America Holdings

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血液腫瘍検査市場2029年：新たな機会を提供する国
• 血液腫瘍検査市場2029年：新たな機会を提供するセグメント
• 血液腫瘍検査市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with hemato oncology testing market share, detailed hemato oncology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from$3.5 billion in 2024 to $3.96 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to increasing cancer incidence, growing awareness and screening programs, rising healthcare expenditure, increasing adoption of personalized medicine, and increasing incidence of blood disorders

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to personalized medicine trends, integration of artificial intelligence, rising geriatric population, advancements in genomic research, and rising demand for early cancer detection. Major trends in the forecast period include technological advancements in genomic testing, liquid biopsy for non-invasive testing, collaborations and partnerships in the industry, regulatory landscape and standardization, and technological advancements.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. As an illustration, the American Cancer Society estimates that in 2023, leukemia is expected to impact approximately 59,610 Americans, leading to 23,710 deaths. Additionally, non-Hodgkin lymphoma is projected to affect 80,550 individuals in the United States, resulting in 20,180 deaths. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

The increasing healthcare expenditure is projected to drive the growth of the hemato-oncology testing market in the coming years. Healthcare expenditure refers to the total funds, both public and private, allocated to the healthcare sector within a specific geographical area, country, or economy over a defined period. Proper allocation of these funds towards hemato-oncology testing enhances diagnostic accuracy, enables personalized treatment approaches, and improves patient outcomes in the complex field of hematopoietic tumors. For example, a report from the Office for National Statistics, a UK-based government department, revealed in May 2024 that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth of only 0.9% in 2022. Therefore, the rise in healthcare expenditure is fueling the growth of the hemato-oncology testing market.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

Major companies in the hemato-oncology testing market are adopting a strategic partnership approach to supplement their hemato-oncology portfolio. Strategic partnerships involve leveraging mutual strengths and resources to achieve shared benefits and success. An instance of this is the collaboration between Servier Laboratories and QIAGEN N.V. to develop an mIDH1 companion diagnostic test. This test is intended to complement Servier's AML therapies by swiftly identifying patients with IDH1 gene mutations using a PCR-based diagnostic test. QIAGEN, a Germany-based molecular diagnostics company, will develop and validate this test under the Master Cooperation Agreement.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemato Oncology Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hemato oncology testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product And Services: Assay Kits And Reagents; Services
• 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma; Other Cancers
• 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS); Other Technologies
• 4) By End User: Hospitals; Academic And Research Institutes; Other End Users
• Subsegments:
• 1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; ELISA Kits; Antibodies
• 2) By Services: Testing Services; Consultation Services; Data Analysis Services
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hemato Oncology Testing Market Characteristics

3. Hemato Oncology Testing Market Trends And Strategies

4. Hemato Oncology Testing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hemato Oncology Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hemato Oncology Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hemato Oncology Testing Market Growth Rate Analysis
• 5.4. Global Hemato Oncology Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hemato Oncology Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hemato Oncology Testing Total Addressable Market (TAM)

6. Hemato Oncology Testing Market Segmentation

• 6.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Assay Kits And Reagents
• Services
• 6.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Multiple Myeloma
• Other Cancers
• 6.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Other Technologies
• 6.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Academic And Research Institutes
• Other End Users
• 6.5. Global Hemato Oncology Testing Market, Sub-Segmentation Of Assay Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PCR Kits
• Next-Generation Sequencing (NGS) Kits
• Flow Cytometry Reagents
• ELISA Kits
• Antibodies
• 6.6. Global Hemato Oncology Testing Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing Services
• Consultation Services
• Data Analysis Services

7. Hemato Oncology Testing Market Regional And Country Analysis

• 7.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hemato Oncology Testing Market

• 8.1. Asia-Pacific Hemato Oncology Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hemato Oncology Testing Market

• 9.1. China Hemato Oncology Testing Market Overview
• 9.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hemato Oncology Testing Market

• 10.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hemato Oncology Testing Market

• 11.1. Japan Hemato Oncology Testing Market Overview
• 11.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hemato Oncology Testing Market

• 12.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hemato Oncology Testing Market

• 13.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hemato Oncology Testing Market

• 14.1. South Korea Hemato Oncology Testing Market Overview
• 14.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hemato Oncology Testing Market

• 15.1. Western Europe Hemato Oncology Testing Market Overview
• 15.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hemato Oncology Testing Market

• 16.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hemato Oncology Testing Market

• 17.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hemato Oncology Testing Market

• 18.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hemato Oncology Testing Market

• 19.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hemato Oncology Testing Market

• 20.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hemato Oncology Testing Market

• 21.1. Eastern Europe Hemato Oncology Testing Market Overview
• 21.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hemato Oncology Testing Market

• 22.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hemato Oncology Testing Market

• 23.1. North America Hemato Oncology Testing Market Overview
• 23.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hemato Oncology Testing Market

• 24.1. USA Hemato Oncology Testing Market Overview
• 24.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hemato Oncology Testing Market

• 25.1. Canada Hemato Oncology Testing Market Overview
• 25.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hemato Oncology Testing Market

• 26.1. South America Hemato Oncology Testing Market Overview
• 26.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hemato Oncology Testing Market

• 27.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hemato Oncology Testing Market

• 28.1. Middle East Hemato Oncology Testing Market Overview
• 28.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hemato Oncology Testing Market

• 29.1. Africa Hemato Oncology Testing Market Overview
• 29.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

• 30.1. Hemato Oncology Testing Market Competitive Landscape
• 30.2. Hemato Oncology Testing Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hemato Oncology Testing Market Other Major And Innovative Companies

• 31.1. Qiagen N.V.
• 31.2. Bio-Rad Laboratories Inc.
• 31.3. Archerdx Inc.
• 31.4. ARUP Laboratories Inc.
• 31.5. Asuragen Inc.
• 31.6. Adaptive Biotechnologies Corp.
• 31.7. Cepheid Inc.
• 31.8. EntroGen Inc.
• 31.9. CORE Diagnostics Inc.
• 31.10. Genoptix Inc.
• 31.11. GenPath Diagnostics
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Siemens AG
• 31.14. Sysmex Corporation
• 31.15. Laboratory Corporation of America Holdings

32. Global Hemato Oncology Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

34. Recent Developments In The Hemato Oncology Testing Market

35. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies

• 35.1 Hemato Oncology Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hemato Oncology Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hemato Oncology Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer